Js Cameron
Guy's Hospital
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Js Cameron.
The Lancet | 1985
D. Taube; D. Gwyn Williams; B. Hartley; C.J. Rudge; Guy Neild; Js Cameron; C.S. Ogg; Kenneth I. Welsh
In a retrospective study of 60 renal-transplant patients immunosuppressed with cyclosporin no specific clinical features differentiated allograft dysfunction responsive to anti-rejection therapy from dysfunction responsive to reduction in cyclosporin dosage. Histologically, allograft dysfunction responsive to anti-rejection therapy was strongly associated with diffuse interstitial infiltration by mononuclear cells, oedema, and haemorrhage, vascular endothelial-cell proliferation, and infiltration of arterial walls by mononuclear cells. Arteriolar medial hypertrophy and hyalinosis were more commonly found in biopsy specimens from allografts with dysfunction responsive to reduction in cyclosporin dose than in those with dysfunction responsive to anti-rejection therapy and those with stable or improving function. Whole-blood cyclosporin concentrations were significantly lower in patients with dysfunction reversed by anti-rejection therapy than in those with dysfunction reversed by reduction in cyclosporin dose or in those with stable function. There was, however, considerable overlap between these groups, so that individual cyclosporin measurements were of little diagnostic value.
The Lancet | 1986
J.C. Flores; C.O.S. Savage; C.M. Lockwood; David Taube; Js Cameron; D.G. Williams; C.S. Ogg
Eight patients with oligoanuric anti-glomerular-basement-membrane (GBM), antibody-mediated glomerulonephritis without lung haemorrhage who were not treated with plasma exchange therapy were reviewed. All had severe crescentic nephritis and required dialysis. Circulating anti-GBM antibodies disappeared gradually and spontaneously in all patients. The autoantibodies became undetectable in five patients after an average of 11 months. No patient recovered renal function. Two patients have been successfully transplanted and anti-GBM nephritis has not recurred. One of these needed a pre-transplant course of plasma exchange and immunosuppression to reduce a slightly raised anti-GBM antibody titre. Of five patients who remain on dialysis, only two cannot be transplanted due to the persistence of circulating autoantibodies. One patient died from causes unrelated to renal disease. Oligoanuric patients with anti-GBM nephritis who need dialysis rarely benefit from aggressive therapy unless lung haemorrhage is present.
Archive | 1986
Vm Yewdall; Dn Bennett-Jones; Js Cameron; C.S. Ogg; D.G. Williams
Concentrations of albumin, transferrin, IgG, C3 and α 2 macroglobulin were measured by radial immunodiffusion in serum and dialysate of patients treated by CAPD. Fibronectin and CH50 were also measured by nephelometry and dialysate opsonic activity was determined. Transport of proteins into peritoneal dialysate was low, varied considerably from patient to patient, and showed little discrimination according to protein size. The dialysate protein level correlated with in vitro opsonic activity.
QJM: An International Journal of Medicine | 1984
A. Serra; Js Cameron; David R. Turner; B. Hartley; C.S. Ogg; G. H. Neild; D. G. Williams; David Taube; C. B. Brown; J. Hicks
QJM: An International Journal of Medicine | 1983
D. Adu; D. Gwyn Williams; David Taube; A. R. Vilches; David R. Turner; Js Cameron; C.S. Ogg
The Lancet | 1994
Js Cameron; F Compton; G Koffman; M. Bewick
Peritoneal Dialysis International | 1990
Simon J. Davies; Vm Yewdall; C.S. Ogg; Js Cameron
Peritoneal Dialysis International | 1989
Dn Bennett-Jones; Vm Yewdall; Cm Gillespie; C.S. Ogg; Js Cameron
The Lancet | 1982
J.T. Papadakis; M. Bewick; Js Cameron; C.J. Rudge; C.S. Ogg; C.B. Brown; R. Donaghey; D. Taube; D.G. Williams
The Lancet | 1982
JamesG. Ackers; Js Cameron; C.S. Ogg; D. Gwyn Williams